Ascendis Pharma's TransCon CNP Shows Significant Benefits in Infants with Achondroplasia, Preventing Surgeries
ASND sits 41% above its 52-week low of $186.054 on light trading volume (0.1× avg).
Summary
Ascendis Pharma announced positive Week 52 data from its reACHin trial for TransCon CNP in infants with achondroplasia. The data showed significant improvements in cranio-cervical junction health, including a mean 3.15 mm enlargement of the foramen magnum, with no patients requiring decompression surgeries. Additionally, the drug demonstrated notable linear growth, with an average annualized growth velocity of 9.9 cm per year and a +0.42 increase in ACH-specific supine length Z-score, alongside an excellent safety profile. This news follows a 6-K filing yesterday reporting the same data and builds on previous positive results for TransCon CNP in older children, expanding the drug's potential market to a critical infant population.
At the time of this announcement, ASND was trading at $262.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3B. The 52-week trading range was $186.05 to $282.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.